10.3 Solid Organ Transplantation Support

The ABO Barrier in Solid Organ Transplantation

Unlike red cell transfusion, where the barrier is entirely about red cell surface antigens, solid organ transplantation (SOT) must respect ABO compatibility because A and B antigens are expressed on vascular endothelium throughout the graft, not just on red cells. If a recipient's preformed isohemagglutinins encounter an ABO-incompatible organ, they can trigger hyperacute rejection: complement-mediated endothelial injury, thrombosis, and graft loss within minutes to hours. For this reason, kidney, liver, heart, and lung transplants have traditionally required an ABO-identical or ABO-compatible donor-recipient pairing, following the same compatibility logic used for plasma or whole blood - a group O donor is the universal organ donor, and a group AB recipient can theoretically accept any ABO type, though practice still favors compatibility over identity only when necessary.

ABO-Incompatible (ABOi) Transplant Protocols

Because compatible organs are scarce, ABO-incompatible (ABOi) transplantation has become an accepted option in select settings, most developed for living-donor kidney transplant. The recipient undergoes desensitization before transplant: plasmapheresis or immunoadsorption to physically remove circulating isohemagglutinins, often combined with rituximab (anti-CD20, depletes B cells) and IVIG, and sometimes splenectomy in older protocols. The immunohematology laboratory's central deliverable is the ABO isohemagglutinin titer, tracked serially before and after transplant to confirm the antibody has been reduced to a safe threshold before crossing the barrier and to monitor for rebound afterward.

A distinct, well-tested pediatric exception exists: infant heart transplant recipients under roughly 12-14 months of age often have not yet developed mature isohemagglutinins, so an ABO-incompatible heart can sometimes be transplanted safely in this narrow age window without desensitization, dramatically expanding the donor pool for critically ill infants.

Liver transplantation is comparatively more tolerant of ABO mismatch than kidney or heart because the liver has intrinsic immunologic tolerance properties, attributed partly to its dual blood supply and large lymphoid mass, so ABO-incompatible liver grafts are used more often in urgent situations, accepting a higher risk of antibody-mediated complications, including the syndrome described below.

Passenger Lymphocyte Syndrome

Passenger lymphocyte syndrome (PLS) is one of the most heavily tested SOT immunohematology topics. It occurs when donor-derived, immunocompetent B lymphocytes travel within the transplanted organ as passengers and, upon engraftment, produce their own antibody against the recipient's ABO antigens - the reverse direction from the usual concern about recipient antibody attacking the graft. The classic scenario is a group O donor organ transplanted into a non-O recipient (A, B, or AB): the donor's naturally occurring anti-A and/or anti-B-producing lymphocytes recognize the recipient's own red cells as foreign and mount a transient humoral response.

PLS is most common after liver transplant, which carries the highest lymphoid load, less common after kidney or heart, and rare after lung. Onset is typically 1-3 weeks post-transplant, and hemolysis is usually mild and self-limited because the donor lymphocyte clone is finite and eventually exhausted or suppressed by immunosuppressive therapy, though severe hemolysis has been reported. Serologically, the recipient develops a positive DAT, a new anti-A and/or anti-B in serum or plasma that was not present pretransplant, and evidence of hemolysis - falling hemoglobin, rising bilirubin and LDH, reticulocytosis. Distinguishing PLS from other causes of post-transplant anemia (surgical blood loss, drug-induced hemolysis, rejection-related consumption) depends on the timing and the new ABO antibody specificity. Management is largely supportive; when transfusion is needed during the hemolytic window, group O red cells avoid amplifying the reaction by not carrying the antigen the new antibody targets.

Pretransplant and Perioperative Immunohematology Support

Beyond the ABO barrier, the immunohematology reference laboratory supports SOT through HLA-based testing that is conceptually distinct from ABO. Panel-reactive antibody (PRA) estimates the percentage of a random donor pool against which a candidate has preformed HLA antibody, and donor-specific antibody (DSA) testing and crossmatch confirm whether the recipient has antibody specifically against the intended donor's HLA type - a positive crossmatch here is a contraindication similar in spirit to ABO incompatibility but immunologically distinct, involving T-cell and B-cell HLA reactivity rather than ABO isohemagglutinins. Routine ABO/Rh typing and antibody screening are still required for perioperative and postoperative transfusion support, and transplant patients frequently receive irradiated cellular components to prevent transfusion-associated graft-versus-host disease in the immunosuppressed host, and may require CMV-reduced-risk products depending on donor and recipient CMV serostatus and organ type.

Crossmatch Methods and Post-Transplant Monitoring

The HLA crossmatch itself has evolved through several methods the exam may reference by name. The original complement-dependent cytotoxicity (CDC) crossmatch mixes recipient serum with donor lymphocytes and complement, scoring cell death as a positive (incompatible) result; it is specific but relatively insensitive to low-level antibody. The flow cytometric crossmatch is more sensitive, detecting lower antibody titers by flow cytometry rather than visible cell lysis, and is now standard at most transplant centers. Solid-phase (Luminex, single-antigen bead) assays identify the exact HLA specificities present in a candidate's serum without needing donor cells at all, which is how a PRA percentage and a virtual crossmatch can be calculated before a specific donor is even identified - a major efficiency gain for deceased-donor allocation. After transplant, DSA levels and organ function are monitored serially, since a rising DSA titer can signal antibody-mediated rejection before a biopsy or creatinine change becomes apparent, paralleling the way an ABO isohemagglutinin titer is trended in ABOi protocols.

Exam Traps

Do not confuse hyperacute rejection (recipient antibody attacking the graft, immediate) with passenger lymphocyte syndrome (donor lymphocyte antibody attacking the recipient, delayed by 1-3 weeks). Do not confuse the ABO barrier, which concerns endothelial antigen expression relevant to organ selection, with the HLA crossmatch and DSA pathway, which concerns antibody-mediated rejection risk - both are tested, but they use different antigens, different assays, and different timing.